StockData
GH Research PLC logo

GH Research PLC (GHRS) stock

GHRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 5, 2026Score 1/30
$18.25−0.02 (-0.11%)

Close on Nov 18, 2026Market cap $1.13BP/E –Yield –

GH Research operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

GH Research's operating income for the twelve months ending Jun 30, 2026 was -$71.49M. For fiscal 2025 it was -$60.72M. The highest annual figure on record is -$310.00K in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$60.72M–
FY2024Dec 31, 2024-$50.31M–
FY2023Dec 31, 2023-$41.22M–
FY2022Dec 31, 2022-$30.55M–
FY2021Dec 31, 2021-$15.10M–
FY2020Dec 31, 2020-$446.00K–
FY2019Dec 31, 2019-$310.00K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$19.46M–
Q1 FY2026Mar 31, 2026-$18.75M–
Q4 FY2025Dec 31, 2025-$16.72M–
Q3 FY2025Sep 30, 2025-$16.57M–
Q2 FY2025Jun 30, 2025-$14.70M–
Q1 FY2025Mar 31, 2025-$12.73M–
Q4 FY2024Dec 31, 2024-$12.94M–
Q3 FY2024Sep 30, 2024-$12.62M–
Q2 FY2024Jun 30, 2024-$13.22M–
Q1 FY2024Mar 31, 2024-$11.53M–
Q4 FY2023Dec 31, 2023-$11.16M–
Q3 FY2023Sep 30, 2023-$9.72M–
Q2 FY2023Jun 30, 2023-$9.93M–
Q1 FY2023Mar 31, 2023-$10.42M–
Q4 FY2022Dec 31, 2022-$9.17M–
Q3 FY2022Sep 30, 2022-$6.63M–
Q2 FY2022Jun 30, 2022-$6.75M–

More GH Research figures

See a number that looks wrong?